Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18312 |
Mc-MMAE
Maleimidocaproyl-monomethylauristatin E,马来酰亚胺基己酰-单甲基澳瑞他汀 E |
Microtubule Associated | Cytoskeletal Signaling |
Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) 是保护基团 (马来酰亚氨基己酰) 与 MMAE 共轭连接得到的化合物。它是微管蛋白抑制剂,可用于偶联抗体。 | |||
T18867 |
Val-Cit-PAB-MMAE
|
||
Val-Cit-PAB-MMAE 是 ADC 的药物-接头偶联物。它包含 ADC 接头(肽 Val-Cit-PAB)和有效的微管蛋白抑制剂 MMAE。 | |||
T17983 |
Fmoc-Val-Cit-PAB-MMAE
|
Others | Others |
Fmoc-Val-Cit-PAB-MMAE 由 ADC 接头 (Fmoc-Val-Cit-PAB) 和强效微管蛋白抑制剂 (MMAE) 组成。 它是一种用于 ADC 的药物-接头偶联物。 | |||
T4232 |
VCMMAE
mc-vc-PAB-MMAE |
Microtubule Associated | Cytoskeletal Signaling |
VCMMAE (mc-vc-PAB-MMAE) 是一种用于 ADC 的药物-接头偶联物,具有抗癌活性,它由 MMAE 和 Vc 连接而成。 | |||
T10948 |
MMAE-d8
D8-MMAE,D8-Monomethyl auristatin E |
Others | Others |
D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE. | |||
T39307 |
Azido-PEG4-Val-Cit-PAB-MMAE
Azido-PEG4-Val-Cit-PAB-MMAE |
||
Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor), connected through the cleavable linker Azido-PEG4-Val-Cit-PAB-OH. | |||
T40308 |
Gly3-VC-PAB-MMAE
Gly3-VC-PAB-MMAE |
||
Gly3-VC-PAB-MMAE is a chemical compound comprised of a cleavable antibody-drug conjugate (ADC) linker, Gly3-VC-PAB, and a potent inhibitor of tubulin, MMAE. It is utilized in the synthesis of ADCs. | |||
T39576 |
DBCO-PEG4-VC-PAB-MMAE
DBCO-PEG4-VC-PAB-MMAE |
||
DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor. | |||
T77876 |
Py-MAA-Val-Cit-PAB-MMAE
AAJ8D6-PY-Val-Cit-MMAE |
||
Py-MAA-Val-Cit-PAB-MMAE (AAJ8D6-PY-Val-Cit-MMAE) 是一款ADC Linker,专用于合成抗体药物偶联物Zapadcine-3a (ADC)。Zapadcine-3a 对抗多种肿瘤表现出高效的活性,其作用机理为定位TRAILR2并通过肿瘤细胞内的溶酶体被摄取,进而针对性释放致死的小分子,从而特异性消灭TRAILR2阳性的肿瘤细胞,并能够有效地治愈肿瘤。 | |||
T40568 |
Fmoc-MMAE
|
||
Fmoc-MMAE, a protective group-conjugated variant of monomethyl auristatin E (MMAE), serves as a powerful inhibitor of tubulin. It finds application in the synthesis of antibody-drug conjugates (ADC). | |||
T6897 |
Monomethyl auristatin E
一甲基澳瑞他汀E,Vedotin,MMAE |
Apoptosis; Microtubule Associated | Apoptosis; Cytoskeletal Signaling |
Monomethyl auristatin E (MMAE) 是海兔毒素 10 的合成衍生物,是一种抗有丝分裂剂,通过阻断微管蛋白的聚合来抑制细胞分裂,并且还具有抑制抗体-药物偶联物的活性。 | |||
T18361 |
MMAE-SMCC
|
Others | Others |
MMAE-SMCC is a drug-linker conjugate designed for antibody-drug conjugates (ADC). It consists of MMAE, a potent inhibitor of mitosis and tubulin, and SMCC, a linker that facilitates the development of ADCs. | |||
T39164 |
MC-betaglucuronide-MMAE-1
|
||
MC-betaglucuronide-MMAE-1 is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), employing MMAE (a tubulin polymerization inhibitor) connected through the cleavable ADC linker MC-betaglucuronide. | |||
T39328 |
SuO-Glu-Val-Cit-PAB-MMAE
|
||
SuO-Glu-Val-Cit-PAB-MMAE is a chemical compound comprising a cleavable ADC linker, SuO-Glu-Val-Cit-PAB, and a potent tubulin inhibitor known as MMAE. It is utilized in the synthesis of antibody-drug conjugates (ADCs). | |||
T18679 |
SC-VC-PAB-MMAE
|
Others | Others |
SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), comprising the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the cleavable linker SC-VC-PAB[1]. | |||
T18736 |
SuO-Val-Cit-PAB-MMAE
|
Others | Others |
SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide. | |||
T18473 |
N3-PEG3-vc-PAB-MMAE
|
Others | Others |
N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity. | |||
T18299 |
Mal-PEG8-Val-Cit-PAB-MMAE
|
Others | Others |
Mal-PEG8-Val-Cit-PAB-MMAE is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. | |||
T18303 |
Mal-Phe-C4-VC-PAB-MMAE
|
Others | Others |
Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker. | |||
T17435 |
Amino-PEG4-Val-Cit-PAB-MMAE
|
Others | Others |
Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable tetraethylene glycol (4 unit PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1]. | |||
T17817 |
DBCO-(PEG)3-VC-PAB-MMAE
|
Others | Others |
DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker. | |||
T17789 |
DBCO-(PEG2-VC-PAB-MMAE)2
|
Others | Others |
DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation. | |||
T17938 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE
|
Others | Others |
Endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable four-unit polyethylene glycol (PEG) linker, specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1]. | |||
T17351 |
Acetylene-linker-Val-Cit-PABC-MMAE
LCB14-0602 |
Others | Others |
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE. | |||
T18250 |
MAL-di-EG-Val-Cit-PAB-MMAE
|
Others | Others |
MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs). | |||
T82582 | Depatuxizumab MMAE | ||
Depatuxizumab MMAE 是抗EGFR抗体 (Depatuxizumab) 与 Monomethylauristatin E (MMAE) 结合形成的抗体-活性分子偶联物 (ADC),能够抑制EGFRvIII突变型以及野生型EGFR在异种移植瘤模型中的生长。 | |||
T77883 |
Val-Ala-PAB-MMAE
|
||
Val-Ala-PAB-MMAE是一种用于抗体药物偶联物(ADC)的药物连接物缀合物,由ADC连接子(Val-Ala-PAB)与微管抑制剂MMAE构成。 | |||
T82380 |
Fmoc-VAP-MMAE
|
||
Fmoc-VAP-MMAE是一种含有微管蛋白抑制剂MMAE的ADC活性分子-linker偶联物,配备了Fmoc保护基团。该复合物由ADC Linker和MMAE构成。 | |||
T77853 |
MC-VA-PABC-MMAE
|
||
MC-VA-PABC-MMAE是一种ADC(Linker为peptide MC-VA-PABC)的活性分子,由Linker与高效微管蛋白抑制剂MMAE通过偶联反应形成。 | |||
T81835 |
MC-betaglucuronide-MMAE-2
|
||
MC-betaglucuronide-MMAE-2 是由微管蛋白聚合抑制剂 MMAE 与 ADC linker MC-betaglucuronide 可降解连接组成的抗体-活性分子偶联物部分。 | |||
T79206 |
MC-EVCit-PAB-MMAE
|
||
MC-EVCit-PAB-MMAE (Linker-Payload 11) 作为一种ADC (drug-linker conjugates) 的代表,由具有功能性的ADC linker (MC-EVCit-PAB) 以及作为有效药物负载的微管蛋白聚合抑制剂MMAE组成。 | |||
T81753 | mp-dLAE-PABC-MMAE | ||
mp-dLAE-PABC-MMAE 是构成抗体药物偶联物 (ADC) 活性部分的化合物。它包括微管蛋白抑制剂 Monomethylauristatin E,并用于ADC的合成。 | |||
T77839 |
Bi-Mc-VC-PAB-MMAE
|
||
Bi-Mc-VC-PAB-MMAE是由ADC linker (Fmoc-Val-Cit-PAB) 与MMAE构成,后者为一种有效的(tubulin)抑制剂,用于偶联抗体。 | |||
T79039 |
GGGDTDTC-Mc-vc-PAB-MMAE
|
||
GGGDTDTC-Mc-vc-PAB-MMAE为一种ADC药物-连接物偶联物,主要由微管蛋白抑制剂Monomethylauristatin E (MMAE)组成。 | |||
T81361 |
PSMA-Val-Cit-PAB-MMAE
|
||
PSMA-Val-Cit-PAB-MMAE是一种靶向前列腺特异性膜抗原(PSMA)的小分子化合物,用MMAE作为药效基团进行前列腺癌治疗。 | |||
T82384 | Fmoc-Gly3-VC-PAB-MMAE | ||
Fmoc-Gly3-VC-PAB-MMAE 是一款用于 ADC 的药物-连接子偶联物,由 MonomethylauristatinE 和连接子构成。 | |||
T77866 |
OH-Glu-Val-Cit-PAB-MMAE
|
||
OH-Glu-Val-Cit-PAB-MMAE 是由可切割的 ADC 连接子 (OH-Glu-Val-Cit-PAB) 与有效的微管蛋白抑制剂 (MMAE) 构成,适用于抗体-活性分子偶联物 (ADC) 的合成。 | |||
T77860 |
TCO-PEG4-VC-PAB-MMAE
|
||
TCO-PEG4-VC-PAB-MMAE为一种抗体偶联药物(ADC)中的活性药物连接子部分,融合了可降解的ADC连接子(TCO-PEG4-VC-PA)与有效的微管蛋白抑制剂MMAE。 | |||
T67428 | mDPR-Val-Cit-PAB-MMAE | ||
mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate. | |||
T77856 |
Ac-Lys-Val-Cit-PABC-MMAE
|
||
Ac-Lys-Val-Cit-PABC-MMAE作为一种抗体偶联药物(ADC)的活性分子部分,由ADC连接子(肽 Ac-Lys-Val-Cit-PABC)与微管蛋白聚合抑制剂MMAE经偶联形成。 | |||
T77885 |
(Aminooxy)acetamide-Val-Cit-PAB-MMAE
|
||
'(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) 是用于ADC药物-接头偶联物合成的中间体。该化合物通过与聚酰胺形成肟键,得到MMAE聚酰胺偶联物,进一步与Trastuzumab偶联,制备成ADC。' | |||
T78521 |
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE
|
Others | Others |
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE(化合物S6)作为抗肿瘤微环境特异性活化的抗癌剂,已被证实能够抑制小鼠肿瘤生长。 | |||
T77857 |
Ac-Lys-Val-Cit-PABC-MMAE formic
|
||
Ac-Lys-Val-Cit-PABC-MMAE (formic) 为一种抗体药物偶联物(ADC)的活性组分。该化合物是由ADC链接子(肽类Ac-Lys-Val-Cit-PABC)与微管蛋白聚合抑制剂Monomethylauristatin E (MMAE) 结合而得。 | |||
T80692 | β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE | ||
β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE 是一种具有选择性的抗增殖活性木耳素-葡糖苷缀合物,对β-葡萄糖醛酸酶处理和未处理的癌细胞体外显示IC50为5.7 nM - 9.7 nM。在HCT-116异种移植小鼠模型中展现出显著的抗肿瘤效果,并且未观察到副作用。 | |||
T18321 |
Mc-Val-Cit-PAB-Cl
|
Others | Others |
Mc-Val-Cit-PAB-Cl 是一种可切割的 ADC 接头,可用于偶联 MMAE 和抗体以形成抗体-MC-vc-MMAE。 | |||
T14348 |
Auristatin E
|
Microtubule Associated | Cytoskeletal Signaling |
Auristatin E 通过阻断微管蛋白的聚合来抑制细胞分裂。它是一种细胞毒性微管蛋白修饰剂,具有强效和选择性抗肿瘤活性。它是一种 MMAE 类似物,是抗体-药物偶联物中的细胞毒素。 | |||
T39595 |
Disitamab vedotin
RC 48,RC-48,RC48 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Disitamab vedotin (RC-48) 是一种抗体-活性分子偶联物 (ADC),包含抗人表皮生长因子受体2 (HER2) 的单克隆抗体,该单克隆抗体通过可降解连接子结合到细胞毒性剂 MMAE。Disitamab vedotin 在不同HER-2表达水平胃癌细胞中显示出抗肿瘤和抗增殖活性且抑制胃癌细胞中HER-2蛋白的表达。 | |||
T15062 | DBCO-NHCO-PEG4-amine | Others | Others |
DBCO-NHCO-PEG4-amine is a cleavable ADC linker used to conjugate MMAE and antibody (e.g., DBCO-VCpAB MMAE and DBCO-TRX MMAE with EC50s of 280 nM and 22 nM in SKBR3 cells, respectively)[1]. | |||
T77186 | Zilovertamab vedotin | ||
Zilovertamab vedotin (VLS-101) 是一种抗体-活性分子偶联物 (ADC), 主要由人源化单克隆抗体 zilovertamab 和单甲基 vedotin 组成的抗微管细胞毒素。该药物通过与肿瘤细胞表面的ROR1结合, 触发快速内化及向溶酶体的转运, 进而裂解释放单甲基 vedotin, 诱导细胞凋亡。适用于癌症的研究领域。 | |||
T15057 |
DBCO-acid
|
Others | Others |
DBCO-acid is a cleavable ADC linker used in the synthesis of ADC linker DBCO-NHS ester, and drug-linker conjugates DBCO-PEG-MMAE[1]. |